BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon Limited has issued a Postal Ballot Notice seeking shareholder approval for ten items of special business. Key proposals include: (1) Revision of Executive Chairperson Ms. Kiran Mazumdar-Shaw's remuneration to Rs. 21 crores per annum (capped at Rs. 25 crores including her Syngene role), effective April 1, 2026; (2) Appointment of Mr. Shreehas Pradeep Tambe as CEO & Managing Director for 5 years from April 1, 2026; (3) Preferential issue of 87,92,317 equity shares at Rs. 376.16 per share to 127 allottees (mostly BBL employees) as consideration for acquiring their BBL shares worth approximately Rs. 330.67 crores; (4) Re-appointment of Ms. Rekha Mehrotra Menon as Independent Director for 5 years; and (5-10) Appointment of six new Independent Directors including Mr. Thomas Jason Roberts as Non-Executive Director. Voting period runs from May 9, 2026 to June 7, 2026.
The appointment of Shreehas Tambe as CEO & MD marks a leadership transition from Kiran Mazumdar-Shaw. The preferential share issuance for BBL share swap may result in dilution but consolidates Biocon's stake in its biologics subsidiary. Multiple board appointments strengthen governance with international independent directors.